AIM ImmunoTech (AIM) Stock Price, News & Analysis

Company Overview

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways.

Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market.

Key Stats

• Today's Range: $0.21 to $0.46
• 50-Day Range: $0.25 to $1.02
• 52-Week Range: $0.21 to $20.35
• Volume: 12.84 million shs
• Average Volume: 25.14 million shs
• Market Capitalization: $2.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

AIM ImmunoTech Stock Analysis - MarketRank™

AIM ImmunoTech scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

AIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

AIM ImmunoTech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of AIM ImmunoTech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AIM ImmunoTech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AIM ImmunoTech has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.72% of the float of AIM ImmunoTech has been sold short.

Short Interest Ratio / Days to Cover

AIM ImmunoTech has a short interest ratio ("days to cover") of 1.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AIM ImmunoTech has recently increased by 21.93%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AIM ImmunoTech does not currently pay a dividend.

Dividend Growth

AIM ImmunoTech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.80

News Sentiment

AIM ImmunoTech has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for AIM ImmunoTech this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.04% of the stock of AIM ImmunoTech is held by insiders.

Percentage Held by Institutions

12.02% of the stock of AIM ImmunoTech is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 5/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:AIM
• CIK: 946644
• Web: aimimmuno.com
• Phone: (352) 448-7797
• Fax: 215-988-1739
• Employees: 20
• Year Founded: 1990

Profitability

• EPS (Trailing Twelve Months): ($24.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.96 million
• Net Margins: -14,123.40%
• Pretax Margin: -14,123.40%
• Return on Equity: N/A
• Return on Assets: -177.72%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 1.01
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 22.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.26 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 8,150,000
• Free Float: 8,145,000
• Market Cap: $2.06 million
• Optionable: Not Optionable
• Beta: 1.24